Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: Effect of octreotide-long acting release (LAR) and cabergoline therapy

Endocrine Journal

Volumn 55, Issue 3, 2008, Pages 595-599

  Tajima, Toshihiro ^a   Tsubaki, Junko ^a   Ishizu, Katsura ^a   Jo, Wakako ^a   Ishi, Nobuaki ^a   Fujieda, Kenji ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Cabergoline; Fibrous dysplasia; McCune Albright syndrome (MAS); Octreotide LAR; Pituitary gigantism

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PROLACTIN;

ADOLESCENT; ALBRIGHT SYNDROME; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RELEASE; GALLSTONE; GENE MUTATION; GIGANTISM; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; VISUAL FIELD DEFECT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; ERGOLINES; FIBROUS DYSPLASIA, POLYOSTOTIC; GIGANTISM; HUMANS; MALE; OCTREOTIDE;

EID: 46749130895     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07E-042     Document Type: Article

References (23)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Speigel AM (1991) Activating mutations of the stimulatory G protein in McCune-Albright syndrome. N Engl J Med 325: 1688-1695.
2. Weinstein LS, Yu S, Warner DR, Liu J (2001) Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22: 675-705.
3. Volkl TMK, Dorr HG (2006) McCune-Albright syndrome: clinical picture and natural history in children and adolescents. J Pediatr Endocrinol Metab Suppl 19: 551-559.
4. Bhansali A, Sharma BS, Sreenivasulu P, Singh P, Vashisth RK, Dash RJ (2003) Acromegaly with fibrous dysplasia: McCune-Albright Syndrome - clinical studies in 3 cases and brief review of literature - Endocr J 50: 793-799.
5. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT (2002) Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 87: 5104-5112.
6. Christoforidis A, Maniadaki I, Stanhope R (2006) McCune-Albright syndrome: growth hormone and prolactin hypersecretion. J Pediatr Endocrinol Metab Suppl 2: 623-625. Review.
7. Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA (1989) Hypersecretion of growth hormone and prolactine in McCune-Albright syndrome. J Clin Endrocrinol Metab 68: 1148-1154.
8. Uwaifo GI, Robey PG, Akintoye SO, Collins MT (2001) Clinical picture: fuel on the fire. Lancet 357: 2011.
9. Sherman SI, Ladenson PW (1992) Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 15:185-190.
10. Chanson P, Dib A, Visot A, Derome PJ (1994) McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 31: 229-234.
11. Feuillan PP, Jones J, Ross JL (1995) Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. J Clin Endocrinol Metab 80: 1357-1360.
12. Sehoof E, Dorr HG, Kiess W, Ludecke DK, Freitag E, Zindel V, Rascher W, Dotsch J (2004) Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism-effect of octreotide therapy. Horm Res 61: 184-189.
13. Ruggieri P, Sim FH, Bond JR, Unni KK (1994) Malignancies in fibrous dysplasia. Cancer 73: 1411-1424.
14. Hansen MR, Moffat JC (2003) Osteosarcoma of the skull base after radiation therapy in a patient with McCune-Albright syndrome: Case report. Skull Base 13:79-83.
15. Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, Young I, Chanson P (2006) McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab 91: 4957-4961.
16. Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT (2006) Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 291: 2960-2966.
17. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T (2006) Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J 53: 125-132.
18. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91: 1397-1403.
19. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87: 4554-4563.
20. Lauberg MRP, Hoejberg AS, Brock-Jacobsen B (2006) Pegvisomant therapy in pituitary gigantism: successful treatment in 12-year-old girl. Eur J Endocrinol 153: 195-201.
21. Chan B, Zacharin M (2006) Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. J Pediatric Endocrinol Metab 19: 75-80.
22. Lala R, Matarazzo P, Andreo M, Marzari D, Bellone J, Corrias A, de Sanctis C; Study Group for Gs alpha Protein Related Diseases of the Italian Society for Pediatric Endocrinology and Diabetes (2006) Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatric Endocrinol Metab suppl 2: 583-593.
23. Glorieux FH, Rauch F (2006) Medical therapy of children with fibrous dysplasia. J Bone Miner Res Suppl 2: 110-113.